Posted: 25 November 2025
Telix announced it has officially opened Telix Manufacturing Solutions (TMS) in Yokohama, Japan, marking the Company’s first cyclotron manufacturing facility in the Asia Pacific region. The site was established to expand access to radiopharmaceuticals for patients in Japan, beginning with clinical supply of TLX250-CDx, a kidney cancer imaging candidate, with plans to support additional investigational and future commercial products subject to regulatory approval.
“The opening of TMS Yokohama is a significant milestone for Telix as it enhances our capacity to meet growing demand for radiopharmaceuticals in Japan and Asia Pacific,” said Raphael Ortiz, CEO International Business and Japan President at Telix. “As the world’s second-largest nuclear medicine market, we have always considered Japan a key country in our clinical and commercial strategy.”
A commemorative lecture was held to mark the occasion, delivered by Professor Jun Hatazawa, Vice President of the Japan Isotope Association and Professor in the Next-Generation Cancer Therapy Research Division at Osaka University. His address, titled Trends and Challenges for the Future of Nuclear Medicine, highlighted emerging advances and ongoing challenges in the field.
The new facility had been positioned as a strategic investment to strengthen Telix’s scientific presence and improve patient access to precision diagnostics and therapies across the region. Once fully operational, TMS Yokohama is expected to support future supply of prostate and brain cancer imaging agents and therapeutic candidates, reinforcing Telix’s growing clinical and commercial footprint in Japan and the broader Asia Pacific.
